US 7,220,410 B2 · Monoclonal antibodies to hepatocyte growth factor

Abstract

The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.

Claims3

Dependent claims

A chimeric or humanized L2G7 monoclonal antibody that binds human hepatocyte growth factor, wherein L2G7 is produced by hybridoma ATCC Number PTA-5162.

Dependencies are inferred from the claim text.

Facts

Application

10/917,915Filed 13 Aug 2004 · continuation in part

Priority

18 Apr 2003

Published

US 2005/0019327 A127 Jan 2005

Granted

22 May 2007

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

C07K 16/22
Against material from animals or humans: against growth factors ; against growth regulators
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/73
Characterized by effect upon binding to a cell or to an antigen: inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
C07K 2317/76
Characterized by effect upon binding to a cell or to an antigen: antagonist effect on antigen, e.g. neutralization or inhibition of binding

Family

Application60/464,061Us provisional application · filed 18 Apr 2003

Application10/825,060Parent of this continuation-in-part · filed 15 Apr 2004

US 2005/0019327 A1Pre-grant publication · published 27 Jan 2005

US 2004/0208876 A1Published application

US 7,220,410 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Claims3

Dependent claims

A chimeric or humanized L2G7 monoclonal antibody that binds human hepatocyte growth factor, wherein L2G7 is produced by hybridoma ATCC Number PTA-5162.

Dependencies are inferred from the claim text.

Facts

Application

10/917,915Filed 13 Aug 2004 · continuation in part

Priority

18 Apr 2003

Published

US 2005/0019327 A127 Jan 2005

Granted

22 May 2007

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

C07K 16/22
Against material from animals or humans: against growth factors ; against growth regulators
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/73
Characterized by effect upon binding to a cell or to an antigen: inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
C07K 2317/76
Characterized by effect upon binding to a cell or to an antigen: antagonist effect on antigen, e.g. neutralization or inhibition of binding

Family

Application60/464,061Us provisional application · filed 18 Apr 2003

Application10/825,060Parent of this continuation-in-part · filed 15 Apr 2004

US 2005/0019327 A1Pre-grant publication · published 27 Jan 2005

US 2004/0208876 A1Published application

US 7,220,410 B2This patent

From the US filing history. Foreign family members aren’t listed.

Monoclonal antibodies to hepatocyte growth factor

Life of this patent

Abstract

Claims3

Monoclonal antibodies to hepatocyte growth factor

Life of this patent

Abstract

Claims3